Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Nucala Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The historical period’s development was fueled by an escalation in the incidence of severe eosinophilic asthma, enhanced identification of eosinophilic conditions, the broadening of biologic treatment protocols, more advanced diagnostic methods for assessing eosinophil levels, and an increase in prescribing by specialized medical professionals.
The anticipated market expansion throughout the forecast period can be attributed to factors such as increased penetration into additional eosinophilic indications, a rising need for personalized respiratory biologics, advancements in monoclonal antibody engineering, broader global reimbursement availability, and a greater adoption of home-based administration methods.
Key trends observed during the forecast period include a growing acceptance of targeted biologic asthma therapies, expanding utilization of IL-5 inhibitors in chronic conditions, the wider application of precision medicine approaches in respiratory care, an increased emphasis on long-term disease management, and enhanced patient stratification practices.
Get A Free Sample Report With In-Depth Market Insights:
Nucala Market Growth Drivers: What’s Behind The Acceleration?
The rising occurrence of asthma is projected to fuel the expansion of the nucala market in the coming years. Asthma is a long-term respiratory ailment marked by inflammation and constriction of the airways, resulting in symptoms such as wheezing, coughing, chest tightness, and breathlessness, frequently brought on by allergens or physical exertion. The rise in asthma cases is linked to factors including environmental pollution, allergens, evolving lifestyles, increasing urbanization, and genetic susceptibility. Nucala aids in mitigating asthma by specifically targeting and blocking interleukin-5 (IL-5), a crucial protein involved in the proliferation and activation of eosinophils, which are white blood cells contributing to airway inflammation in asthma, thus alleviating symptoms and reducing the frequency of asthma attacks. For example, in February 2023, as per NHS England, a UK-based government department, 5.4 million people in the UK are undergoing asthma treatment, with approximately 160,000 new diagnoses each year, and work-related asthma constitutes 9-15% of adult-onset cases. Consequently, the growing prevalence of asthma is boosting the nucala market’s development.
Nucala Market Segment Landscape: Which Areas Lead Development?
The nucala market covered in this report is segmented –
1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Chronic Obstructive Pulmonary Disease (COPD), Other Eosinophilic Disorders
2) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
3) By End User: Hospitals, Clinics, Home Care Settings
Nucala Market Trends: What’s Defining The Industry’s Next Phase?
Companies operating significantly within the Nucala market are concentrating on developing innovative solutions, such as ready-to-use injectable formulations, to satisfy the increasing demand for patient convenience and enhance treatment adherence. A ready-to-use injectable form is a pre-prepared pharmaceutical product that does not require any further dilution or mixing before it is administered. For example, in May 2025, GlaxoSmithKline Plc, a UK-based pharmaceutical company, secured approval from the US FDA for Nucala (mepolizumab) for use in treating adults with chronic obstructive pulmonary disease (COPD) presenting with an eosinophilic phenotype. This expansion of indication enables a targeted therapy approach for COPD patients with a high unmet need, bolstered by positive results from the MATINEE and METREX Phase III trials.
Nucala Market Industry Leaders And Competitive Landscape
Major companies operating in the nucala market are GlaxoSmithKline plc
View The Full Nucala Market Report:
Nucala Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the nucala market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucala market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
